Passage Bio, Inc.
NASDAQ Global SelectTotal Valuation
Passage Bio, Inc. carries a market capitalization of 15.42M, placing it among publicly traded companies globally. Its enterprise value stands at -8.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15.42M |
| Enterprise Value | -8.45M |
Share Statistics
Passage Bio, Inc. currently has 3.22M shares outstanding.
| Shares Outstanding | 3.22M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | -0.47 |
| P/OCF Ratio | -0.47 |
Financial Position
Passage Bio, Inc. maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.22 |
| Quick Ratio | 1.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -169.09 |
| Return on Assets (ROA) | -69.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Passage Bio, Inc.'s stock has declined approximately -37.82383% over the past 52 weeks. The 50-day moving average sits at 4.68, while the 200-day moving average is 7.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -37.82383% |
| 50-Day Moving Average | 4.68 |
| 200-Day Moving Average | 7.39 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -37.58M, while operating income came in at -38.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -38.09M |
| Pretax Income | -36.11M |
| Net Income | -36.11M |
| EBITDA | -37.58M |
| EBIT | -38.09M |
| Earnings Per Share (EPS) | -11.29 |
Balance Sheet
Total book value stands at 4.46M, with working capital of 4.46M providing operational flexibility.
| Cash & Cash Equivalents | 24.16M |
| Total Debt | N/A |
| Net Debt | -24.15M |
| Equity (Book Value) | 4.46M |
| Book Value Per Share | 1.38 |
| Working Capital | 4.46M |
Cash Flow
Passage Bio, Inc. produced -33.50M in operating cash flow over the past twelve months.
| Operating Cash Flow | -33.50M |
| Capital Expenditures | N/A |
| Free Cash Flow | -33.50M |
| FCF Per Share | -10.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.06 |
| FCF Yield | -214.67 |
Stock Splits
Passage Bio, Inc.'s most recent stock split took place on July 14, 2025 with a 20:1 split ratio.
| Last Split Date | 7/14/2025 |
| Split Ratio | 20:1 |
Scores
Passage Bio, Inc. posts an Altman Z-Score of -44.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -44.37 |